The immunomodulator, ammonium trichloro[1,2-ethanediolato-O,O']-tellurate, suppresses the propagation of herpes simplex virus 2 by reducing the infectivity of the virus progeny

Sheinboim,D.; Hindiyeh,M.; Mendelson,E.; Albeck,M.; Sredni,B.; Dovrat,S.

doi:10.3892/ijmm.2015.2197

The immunomodulator, ammonium trichloro[1,2-ethanediolato-O,O']-tellurate, suppresses the propagation of herpes simplex virus 2 by reducing the infectivity of the virus progeny

Authors:
- D. Sheinboim
- M. Hindiyeh
- E. Mendelson
- M. Albeck
- B. Sredni
- S. Dovrat
View Affiliations

Affiliations: Central Virology Laboratory, The Chaim Sheba Medical Center, Ramat‑Gan, Israel, Department of Chemistry, Faculty of Exact Sciences, Bar‑Ilan University, Ramat‑Gan, Israel, The SAFDIÉ Cancer, AIDS and Immunology Research (CAIR) Institute, The Mina and Everard Goodman Faculty of Life Sciences, Bar‑Ilan University, Ramat‑Gan, Israel
Published online on: April 24, 2015 https://doi.org/10.3892/ijmm.2015.2197
Pages: 231-238

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Persistent investigations for the identification of novel anti-herpetic drugs are being conducted worldwide, as current treatment options are sometimes insufficient. The immunomodulator, ammonium trichloro[1,2‑ethanediolato‑O,O']‑tellurate (AS101), a non‑toxic tellurium (Ⅳ) compound, has been shown to exhibit anti‑viral activity against a variety of viruses in cell cultures and in animal models. In the present study, the anti‑viral activity of AS101 against herpes simplex virus (HSV)‑1 and 2 was investigated in vitro. The results demonstrated that AS101 significantly restricted HSV‑2-induced plaque formation and reduced the infectivity of the HSV‑2 yield, while HSV‑1 was affected to a lesser extent. The incubation of mature HSV‑1 and HSV‑2 viruses with AS101 had no effect on viral infectivity, indicating that the compound interrupts de novo viral synthesis. The addition of AS101 at up to 9 h post‑infection had almost the same effect as did the addition of the drug together with the virus (it maintained 80% of its total anti‑viral capacity). Quantitative PCR and immunofluoresence staining of viral structural proteins revealed that the viral DNA and protein synthesis stages were not interrupted by the administration of AS101. By contrast, in the presence of the compound, significantly fewer viable viruses (≥2 log reduction) were recovered from the AS10‑treated cell cultures. Of note, when we determined the viability of the intracellular virus, formed in the presence of the compound, a less severe (≤1 log) effect was observed. Taken together, these data strongly suggest that AS101 primarily interferes with late stages of viral replication, such as viral particle envelopment or egress, leading to the production of a defective virus progeny.

View Figures

View References

1	Wilson C: Reproductive endocrinology: AS101 might prevent chemotherapy-induced infertility. Nat Rev Endocrinol. 9:4412013. View Article : Google Scholar : PubMed/NCBI
2	Rowe AM, St Leger AJ, Jeon S, Dhaliwal DK, Knickelbein JE and Hendricks RL: Herpes keratitis. Prog Retin Eye Res. 32:88–101. 2013. View Article : Google Scholar
3	Rozenberg F, Deback C and Agut H: Herpes simplex encephalitis: From virus to therapy. Infect Disord Drug Targets. 11:235–250. 2011. View Article : Google Scholar : PubMed/NCBI
4	Taylor TJ, Brockman MA, McNamee EE and Knipe DM: Herpes simplex virus. Front Biosci. 7:d752–d764. 2002. View Article : Google Scholar : PubMed/NCBI
5	Piret J and Boivin G: Resistance of herpes simplex viruses to nucleoside analogues: Mechanisms, prevalence, and management. Antimicrob Agents Chemother. 55:459–472. 2011. View Article : Google Scholar :
6	Zhang Y, But PP, Ooi VE, Xu HX, Delaney GD, Lee SH and Lee SF: Chemical properties, mode of action, and in vivo anti-herpes activities of a lignin-carbohydrate complex from Prunella vulgaris. Antiviral Res. 75:242–249. 2007. View Article : Google Scholar : PubMed/NCBI
7	Yarmolinsky L, Zaccai M, Ben-Shabat S, Mills D and Huleihel M: Antiviral activity of ethanol extracts of Ficus binjamina and Lilium candidum in vitro. N Biotechnol. 26:307–313. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bernstein DI, Miller RL and Harrison CJ: Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development. Antiviral Res. 20:45–55. 1993. View Article : Google Scholar : PubMed/NCBI
9	Abad MJ, Guerra JA, Bermejo P, Irurzun A and Carrasco L: Search for antiviral activity in higher plant extracts. Phytother Res. 14:604–607. 2000. View Article : Google Scholar : PubMed/NCBI
10	Hirokawa D, Woldow A, Lee SN and Samie F: Treatment of recalcitrant herpes simplex virus with topical imiquimod. Cutis. 88:276–277. 2011.
11	Albeck A, Weitman H, Sredni B and Albeck M: Tellurium compounds: Selective Inhibition of cysteine proteases and model reaction with thiols. Inorg Chem. 37:1704–1712. 1998. View Article : Google Scholar
12	Halperin-Sheinfeld M, Gertler A, Okun E, Sredni B and Cohen HY: The Tellurium compound, AS101, increases SIRT1 level and activity and prevents type 2 diabetes. Aging (Albany NY). 4:436–447. 2012.
13	Sredni B, Geffen-Aricha R, Duan W, Albeck M, Shalit F, Lander HM, Kinor N, Sagi O, Albeck A, Yosef S, et al: Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson’s disease models. FASEB J. 21:1870–1883. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sredni B, Gal R, Cohen IJ, Dazard JE, Givol D, Gafter U, Motro B, Eliyahu S, Albeck M, Lander HM, et al: Hair growth induction by the Tellurium immunomodulator AS101: Association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression. FASEB J. 18:400–402. 2004.
15	Sredni B, Rosenthal-Galili Z, Michlin H, Sobelman D, Seger Y, Blagerman S, Kalechman Y and Rager-Zisman B: Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by AS101. Immunol Lett. 43:159–165. 1994. View Article : Google Scholar : PubMed/NCBI
16	Vonsover A, Loya S, Sredni B, Albeck M, Gotlieb-Stematsky T, Araf O and Hizi A: Inhibition of the reverse transcriptase activity and replication of human immunodeficiency virus type 1 by AS101 in vitro. AIDS Res Hum Retroviruses. 8:613–623. 1992. View Article : Google Scholar : PubMed/NCBI
17	Indenbaum V, Bin H, Makarovsky D, Weil M, Shulman LM, Albeck M, Sredni B and Mendelson E: In vitro and in vivo activity of AS101 against West Nile virus (WNV). Virus Res. 166:68–76. 2012. View Article : Google Scholar : PubMed/NCBI
18	Friedman M, Bayer I, Letko I, Duvdevani R, Zavaro-Levy O, Ron B, Albeck M and Sredni B: Topical treatment for human papillomavirus-associated genital warts in humans with the novel tellurium immunomodulator AS101: Assessment of its safety and efficacy. Br J Dermatol. 160:403–408. 2009. View Article : Google Scholar
19	Cantatore A, Randall SD, Traum D and Adams SD: Effect of black tea extract on herpes simplex virus-1 infection of cultured cells. BMC Complement Altern Med. 13:1392013. View Article : Google Scholar : PubMed/NCBI
20	Filén F, Strand A, Allard A, Blomberg J and Herrmann B: Duplex real-time polymerase chain reaction assay for detection and quantification of herpes simplex virus type 1 and herpes simplex virus type 2 in genital and cutaneous lesions. Sex Transm Dis. 31:331–336. 2004. View Article : Google Scholar : PubMed/NCBI
21	Snoeck R: Antiviral therapy of herpes simplex. Int J Antimicrob Agents. 16:157–159. 2000. View Article : Google Scholar : PubMed/NCBI
22	Wilson SS, Fakioglu E and Herold BC: Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther. 7:559–568. 2009. View Article : Google Scholar : PubMed/NCBI
23	Koyama AH and Uchida T: Quantitative studies on the maturation process of herpes simplex virus type 1 in Vero cells. Virus Res. 10:281–285. 1988. View Article : Google Scholar : PubMed/NCBI
24	Norais N, Tang D, Kaur S, Chamberlain SH, Masiarz FR, Burke RL and Marcus F: Disulfide bonds of herpes simplex virus type 2 glycoprotein gB. J Virol. 70:7379–7387. 1996.PubMed/NCBI
25	Foster TP and Kousoulas KG: Genetic analysis of the role of herpes simplex virus type 1 glycoprotein K in infectious virus production and egress. J Virol. 73:8457–8468. 1999.PubMed/NCBI
26	Foster TP, Chouljenko VN and Kousoulas KG: Functional and physical interactions of the herpes simplex virus type 1 UL20 membrane protein with glycoprotein K. J Virol. 82:6310–6323. 2008. View Article : Google Scholar : PubMed/NCBI
27	Gianni T and Campadelli-Fiume G: αVβ3-integrin relocalizes nectin1 and routes herpes simplex virus to lipid rafts. J Virol. 86:2850–2855. 2012. View Article : Google Scholar :
28	Parry C, Bell S, Minson T and Browne H: Herpes simplex virus type 1 glycoprotein H binds to alphavbeta3 integrins. J Gen Virol. 86:7–10. 2005. View Article : Google Scholar
29	Mingo RM, Han J, Newcomb WW and Brown JC: Replication of herpes simplex virus: Egress of progeny virus at specialized cell membrane sites. J Virol. 86:7084–7097. 2012. View Article : Google Scholar : PubMed/NCBI
30	Ikeda K, Yamasaki H, Minami S, Suzuki Y, Tsujimoto K, Sekino Y, Irie H, Arakawa T and Koyama AH: Arginine inactivates human herpesvirus 2 and inhibits genital herpesvirus infection. Int J Mol Med. 30:1307–1312. 2012.PubMed/NCBI
31	Daniel-Hoffmann M, Albeck M, Sredni B and Nitzan Y: A potential antimicrobial treatment against ESBL-producing Klebsiella pneumoniae using the tellurium compound AS101. Arch Microbiol. 191:631–638. 2009. View Article : Google Scholar : PubMed/NCBI